Physician profile
William H Hoffman
NPI 1568479244
$3,278.46
in general payments reported to CMS, 2019-2025
14 companies · $458 in 2025
The $458 reported for 2025 was more than what 82% of Dermatopathology (Pathology) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $320 · 2021: $122 · 2022: $741 · 2023: $701 · 2024: $577 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,735.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $644.34 | 2022-2024 | |
| Regeneron Healthcare Solutions, INC. | $611.72 | 2021-2025 | Dupixent, Libtayo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $287.45 | 2019-2020 | |
| Leo Pharma INC. | $219.69 | 2022-2024 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $209.49 | 2023-2025 | Sotyktu |
| Janssen Biotech, INC. | $206.68 | 2024-2025 | Tremfya |
| Pfizer INC. | $204.16 | 2019-2023 | |
| Stemline Therapeutics INC. | $152.15 | 2020 | |
| Arcutis Biotherapeutics, INC. | $137.26 | 2025 | Zoryve |
| Genzyme Corporation | $129.78 | 2023 | |
| Incyte Corporation | $125.00 | 2024 | Opzelura |
| Journey Medical Corporation | $123.54 | 2022 | |
| Aclaris Therapeutics, INC. | $118.74 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108.46 | 2023 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.